Skip to main content
Premium Trial:

Request an Annual Quote

Axaron Inks Deal for Axaminer Technology with Max Planck Institute

NEW YORK, Jan. 26 (GenomeWeb News) - Axaron Bioscience said today that it has signed a service contract to provide its Axaminer gene expression profiling technology to the Max Planck Institute for Medical Research.


Under the arrangement, said Axaron, the technology will be used by Max Planck Institute researchers in a project analyzing the molecular processes of glutamate-mediated signal transduction.


"We are hoping these investigations will lead to a better understanding of neurological diseases such as stroke," Peter Seeburg, director of the department of molecular neurobiology at the Max Planck Institute, said in a statement.


Specific terms of the deal were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.